Genmab — Maj 2020
-
@Solsen du har ret - Roche cd3/cd20 er sat på hold. Jan nævner det 42 minutter inde i webcast
-
@kkjoel - the market can foresee to get a very very impressive upfront. 49 minutter inde i webcast
-
The 2 most impotant studies (epco og PD-L1x4-1BB) are uneffected by corona virus, and still recruiting new patients - 50 minutter inde i webcast
-
God morgen
-
God morgen.
-
Nordea beholder Genmab på HOLD med fair value på 1402
-
Transcript , lets have another look https://finance.yahoo.com/news/edited-transcript-gen-co-earnings-053720106.html
-
Jefferies raises price target on Genmab to DKK 1950 from DKK 1900
-
Danske Bank: Expectation of an Epcoritamab deal is growing and pipeline development is on track for a larger number of important data readouts in the near term. The FY2020 outlook is unchanged, despite COVID-19. We keep our Buy and raise the 12M TP to DKK2,000 (DKK1,820), reflecting the positive developments in the pipeline.
-
Roche har åbenbart sat sit cd3/cd20 studie på hold. Kan det være fordi de har indset at Genmabs cd3/cd20 er "best in class", og derfor ønsker at være Genmabs partner på dette?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind